Loading
A phase 3 trial of telisotuzumab adizutecan, docetaxel and ramucirumab in lung cancer, run by AbbVie, not yet recruiting.
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07821684 by AbbVie, with a registry enrolment figure of 660 participants, started 2027-01-06 and due to reach its primary completion in 2031-04. Interventions recorded: Telisotuzumab Adizutecan; Docetaxel; Ramucirumab. Conditions listed: Non-Squamous Non-Small Cell Lung Cancer. Primary outcome: Objective Response (OR) Based on Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1; Overall Survival (OS). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed metastatic/locally advanced non-squamous NSCLC". No results are recorded here; the registry entry is the source.
Shares Ramucirumab, Docetaxel, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ramucirumab, Docetaxel, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ramucirumab, EGFR-mutated non-small-cell lung cancer, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Antibody-drug conjugate (ADC) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Docetaxel, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.